{
    "Trade/Device Name(s)": [
        "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S PCT sensitive KRYPTOR"
    ],
    "Submitter Information": "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S GmbH",
    "510(k) Number": "K171338",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN150009",
        "K162827"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PRI",
        "PMT",
        "NTM"
    ],
    "Summary Letter Date": "May 2, 2017",
    "Summary Letter Received Date": "May 8, 2017",
    "Submission Date": "May 2, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Procalcitonin (PCT)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S KRYPTOR analyzer family"
    ],
    "Method(s)/Technology(ies)": [
        "Immunofluorescent assay",
        "Time-Resolved Amplified Cryptate Emission (TRACE) technology"
    ],
    "Methodologies": [
        "Homogeneous sandwich immunoassay",
        "Automated fluorescent detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control",
        "Analyzer",
        "Automated system",
        "Consumable"
    ],
    "Document Summary": "FDA 510(k) summary for B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S PCT sensitive KRYPTOR immunofluorescent assay for procalcitonin using TRACE technology to aid assessment of sepsis risk and antibiotic management",
    "Indications for Use Summary": "Aids in risk assessment of progression to severe sepsis and septic shock, cumulative 28-day mortality risk, and decision making on antibiotic initiation/discontinuation in patients with suspected or confirmed sepsis or lower respiratory tract infections, when used with clinical assessment",
    "fda_folder": "Microbiology"
}